MHRA concludes positive safety profile for Pfizer/BioNTech vaccine in 12- to 15-year-olds

The MHRA has authorised an extension to the current UK approval of the Pfizer/BioNTech COVID-19 vaccine that allows use in 12-15 year-olds, following a rigorous review of its safety, quality and effectiveness in this age group by the MHRA and the Commission on Human Medicines.

Medicines and Healthcare products Regulatory Agency